Grafted opthalmic devices containing deactivated regions and processes for their preparation and use

HK40137358APending Publication Date: 2026-09-11JOHNSON & JOHNSON VISION CARE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124568
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-30
Filing Date
2026-06-09
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed are ophthalmic devices formed by a process comprising: (a) providing a reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the reactive composition to a first activation step such that the reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator; (c) deactivating at least a portion of the covalently bound activatable free radical initiator at one or more selective regions of the crosslinked substrate network such that the crosslinked substrate network contains retained covalently bound activatable free radical initiator outside of the one or more selective regions and optionally within the one or more selective regions; (d) contacting the crosslinked substrate network with a grafting composition containing one or more ethylenically unsaturated compounds, wherein the contacting is conducted under conditions such that the grafting composition penetrates into the crosslinked substrate network; and (e) activating the retained covalently bound activatable free radical initiator such that the grafting composition polymerizes with the crosslinked substrate network, thereby forming grafted polymeric networks, outside of the selective regions and optionally partially within the selective regions.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention discloses an ophthalmic device prepared by a method comprising: (a) providing a reactive composition comprising: (i) a polymerization initiator capable of forming two or more free radicals upon initial activation, wherein at least one free radical is further activated by subsequent activation; (ii) one or more vinyl unsaturated compounds; and (iii) a crosslinking agent; (b) subjecting the reactive composition to initial activation to polymerize it into a crosslinked substrate network comprising a covalently bound activatable free radical initiator; (c) deactivating at least a portion of the covalently bound activated free radical initiator in one or more selective regions of the crosslinked substrate network, such that the crosslinked substrate network retains the covalently bound activated free radical initiator outside and optionally within the selective regions; (d) contacting the crosslinked substrate network with a graft composition containing one or more vinyl unsaturated compounds, wherein the contact is performed under conditions where the graft composition permeates into the crosslinked substrate network; and (e) The activated free radical initiator, which is retained by activating covalent bonding, causes the grafted composition to polymerize with the crosslinked substrate network, thereby forming a grafted polymer network outside and optionally within the selective region.

Claims

Attorney Docket No.: VTN6149WOPCT1 We claim:

1. An ophthalmic device formed by a process comprising: a) providing a reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; b) subjecting the reactive composition to a first activation step such that the reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator; c) deactivating at least a portion of the covalently bound activatable free radical initiator at one or more selective regions of the crosslinked substrate network such that the crosslinked substrate network contains retained covalently bound activatable free radical initiator outside of the one or more selective regions; d) contacting the crosslinked substrate network with a grafting composition containing one or more ethylenically unsaturated compounds, wherein the contacting is conducted under conditions such that the grafting composition penetrates into the crosslinked substrate network; and e) activating the retained covalently bound activatable free radical initiator such that the grafting composition polymerizes with the crosslinked substrate network, thereby forming grafted polymeric networks outside of the selective regions.

2. The ophthalmic device of claim 1 wherein the deactivating of step (c) varies spatially within the ophthalmic device.

3. The ophthalmic device of any one of claims 1 to 2 wherein the deactivating step (c) is achieved by irradiation at a wavelength capable of activating the initiator, wherein the initiation is conducted in an atmosphere containing oxygen gas.

4. The ophthalmic device of claim 1 wherein the grafting composition of step (d) contains a crosslinker.

5. The ophthalmic device of claim 1 wherein the grafting composition of step (d) is free of a crosslinker.Attorney Docket No.: VTN6149WOPCT1 6. The ophthalmic device of claim 1 wherein in step (c), only a portion of the covalently bound activatable free radical initiator is inactivated at the selective regions such that step (e) includes forming a grafted network partially within the selective regions.

7. The ophthalmic device of any one of claims 1 to 6 wherein the one or more ethylenically unsaturated compounds of step (a) comprise one or more polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O- vinylether, O-vinylcarbonate, O-vinylcarbamate, C2-12 alkenyl, C2-12 alkenylphenyl, C2-12 alkenylnaphthyl, and C2-6 alkenylphenyl-C1-6 alkyl.

8. The ophthalmic device of any one of claims 1 to 7 wherein the one or more ethylenically unsaturated compounds of step (d) comprise one or more polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O- vinylether, O-vinylcarbonate, O-vinylcarbamate, C2-12 alkenyl, C2-12 alkenylphenyl, C2-12 alkenylnaphthyl, and C2-6alkenylphenyl-C1-6alkyl.

9. The ophthalmic device of any one of claims 1 to 8 wherein the polymerization initiator is a bisacylphosphine oxide, a bisacylphosphane oxide, a di-azo compound, a di-peroxide compound, an azo-bis(monoacylphosphine oxide), an azo-bis(monoacylphosphane oxide), a peroxy-bis(monoacylphosphine oxide), a peroxy-bis(monoacylphosphane oxide), an azo- bis(alpha-hydroxy ketone), a peroxy-bis(alpha-hydroxy ketone), an azo-bis(1,2-diketone), a peroxy-bis(1,2-diketone), a germanium based compound, tert-butyl 7-methyl-7-(tert- butylazo)peroxyoctanoate, or combinations thereof.

10. The ophthalmic device of any one of claims 1 to 9 wherein the polymerization initiator is a bisacylphosphine oxide or a bis(acyl)phosphane oxide.

11. The ophthalmic device of any one of claims 1 to 10 that is in the form of a hydrogel and wherein the reactive composition contains one or more silicone-containing components, and the grafting composition contains one or more hydrophilic reactive components.

12. The ophthalmic device of any one of claims 1 to 11 wherein the reactive composition, the grafting composition, or both the reactive composition and the grafting composition contain one or more additives selected from UV absorbers, photochromic compounds, pharmaceuticalAttorney Docket No.: VTN6149WOPCT1 compounds, nutraceutical compounds, antimicrobial compounds, reactive tints, pigments, copolymerizable dyes, non-polymerizable dyes, release agents, wetting agents, and release agents.

13. The ophthalmic device of any one of claims 1 to 12 further comprising: following step (e), contacting the crosslinked substrate network with a second grafting composition containing one or more ethylenically unsaturated compounds and activating retained covalently bound activatable free radical initiator such that the second grafting composition polymerizes with the crosslinked substrate network outside of the selective regions and optionally partially within the selective regions.

14. The ophthalmic device of any one of claims 1 to 13 wherein steps (a) and (b) are performed in a mold assembly comprised of a front mold and a back mold, the front mold and the back mold defining and enclosing a cavity in the shape of the ophthalmic device therebetween, and process steps (c), (d), and (e) are performed in the mold assembly after the back mold has been removed.

15. The ophthalmic device of any one of claims 1 to 14 wherein the ophthalmic device is selected from the group consisting of a contact lens, an intraocular lens, a punctal plug, and an ocular insert.

16. The ophthalmic device of claim 15 wherein the ophthalmic device is a contact lens or an intraocular lens.

17. An ophthalmic device that is a reaction product of a composition comprising: a) a crosslinked substrate network containing covalently bound activatable free radical initiators outside of one or more selective regions and optionally partially within the one or more selective regions; and b) a grafting composition containing one or more ethylenically unsaturated compounds, wherein the grafting composition is localized in the crosslinked substrate network where there are retained covalently bound activatable free radical initiators.

18. The ophthalmic device of claim 17 wherein the concentration of the retained covalently bound activatable free radical initiators varies spatially within crosslinked substrate network.Attorney Docket No.: VTN6149WOPCT1 19. The ophthalmic device of any one of claims 17 to 18 wherein the crosslinked substrate network is the reaction product of a reactive composition comprising: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker.

20. The ophthalmic device of claim 19 wherein the polymerization initiator is a bisacylphosphine oxide, a bisacylphosphane oxide, a di-azo compound, a di-peroxide compound, an azo-bis(monoacylphosphine oxide), an azo-bis(monoacylphosphane oxide), a peroxy- bis(monoacylphosphine oxide), a peroxy-bis(monoacylphosphane oxide), an azo-bis(alpha- hydroxy ketone), a peroxy-bis(alpha-hydroxy ketone), an azo-bis(1,2-diketone), a peroxy- bis(1,2-diketone), a germanium based compound, tert-butyl 7-methyl-7-(tert- butylazo)peroxyoctanoate, or combinations thereof.

21. The ophthalmic device of claim 20 wherein the polymerization initiator is a bisacylphosphine oxide or a bis(acyl)phosphane oxide.

22. The ophthalmic device of claim 17 wherein the covalently bound activatable free radical initiators are selected from the group consisting of monoacylphosphine oxides, bisacylphosphine oxides, and combinations thereof.

23. The ophthalmic device of claim 17 wherein the crosslinked substrate network is formed by the thermal free radical polymerization of a reactive monomer mixture comprising at least one reactive component having at least one pendant group selected from the group consisting of monoacylphosphine oxide, bisacylphosphine oxide, and combinations thereof.

24. The ophthalmic device of any one of claims 17 to 23 wherein the one or more ethylenically unsaturated compounds in the grafting composition and the reactive composition comprise polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O-vinylether, O-vinylcarbonate, O-vinylcarbamate, C2-12alkenyl, C2-12alkenylphenyl, C2-12alkenylnaphthyl, and C2-6alkenylphenyl-C1-6alkyl.Attorney Docket No.: VTN6149WOPCT1 25. The ophthalmic device of any one of claims 17 to 24 wherein the crosslinked substrate network is formed from one or more silicone-containing components and the grafting composition contains hydrophilic reactive components.

26. The ophthalmic device of any one of claims 17 to 24 wherein the crosslinked substrate network is formed from one or more hydrophilic reactive components and the grafting composition contains one or more silicone-containing components.

27. The ophthalmic device of any one of claims 17 to 24 wherein the crosslinked substrate network is formed from one or more hydrophilic reactive components and the grafting composition contains hydrophilic reactive components.

28. The ophthalmic device of any one of claims 17 to 24 wherein the crosslinked substrate network is formed from one or more silicone-containing components and the grafting composition contains one or more silicone-containing components.

29. The ophthalmic device of any one of claims 17 to 28 wherein the crosslinked substrate network, the grafting composition, or both the crosslinked substrate network and the grafting composition contain one or more additives selected from UV absorbers, photochromic compounds, pharmaceutical compounds, nutraceutical compounds, antimicrobial compounds, tints, pigments, dyes, dyes, release agents, and wetting agents.

30. The ophthalmic device of any one of claims 17 to 29 wherein the ophthalmic device is selected from the group consisting of a contact lens, an intraocular lens, a punctal plug, and an ocular insert.

31. The ophthalmic device of claim 30 wherein the ophthalmic device is a contact lens or an intraocular lens.

32. A process for making an ophthalmic device, the process comprising: a) providing a reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker;Attorney Docket No.: VTN6149WOPCT1 b) subjecting the reactive composition to a first activation step such that the reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator; c) deactivating at least a portion of the covalently bound activatable free radical initiator at one or more selective regions of the crosslinked substrate network such that the crosslinked substrate network contains retained covalently bound activatable free radical initiator outside of the one or more selective regions; d) contacting the crosslinked substrate network with a grafting composition containing one or more ethylenically unsaturated compounds, wherein the contacting is conducted under conditions such that the grafting composition penetrates into the crosslinked substrate network; and e) activating the retained covalently bound activatable free radical initiator such that the grafting composition polymerizes with the crosslinked substrate network, thereby forming grafted polymeric networks outside of the selective regions.

33. The ophthalmic device of claim 32 wherein the deactivating of step (c) varies spatially within the ophthalmic device.

34. The ophthalmic device of any one of claims 32 to 33 wherein the deactivating step (c) is achieved by irradiation in an oxygen gas atmosphere.

35. The process of claim 32 wherein the grafting composition of step (d) contains a crosslinker.

36. The process of claim 32 wherein the grafting composition of step (d) is free of a crosslinker.

37. The process of claim 32 wherein in step (c), only a portion of the covalently bound activatable free radical initiator is inactivated at the selective regions such that step (e) includes forming a grafted network partially within the selective regions.

38. The process of any one of claims 32 to 37 wherein the one or more ethylenically unsaturated compounds of step (a) comprise one or more polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O-Attorney Docket No.: VTN6149WOPCT1 vinylether, O-vinylcarbonate, O-vinylcarbamate, C2-12 alkenyl, C2-12 alkenylphenyl, C2-12 alkenylnaphthyl, and C2-6 alkenylphenyl-C1-6 alkyl.

39. The process of any one of claims 32 to 38 wherein the one or more ethylenically unsaturated compounds of step (e) comprise one or more polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O- vinylether, O-vinylcarbonate, O-vinylcarbamate, C2-12alkenyl, C2-12alkenylphenyl, C2-12alkenylnaphthyl, and C2-6 alkenylphenyl-C1-6 alkyl.

40. The process of any one of claims 32 to 39 wherein the polymerization initiator is a bisacylphosphine oxide, a bisacylphosphane oxide, a di-azo compound, a di-peroxide compound, an azo-bis(monoacylphosphine oxide), an azo-bis(monoacylphosphane oxide), a peroxy- bis(monoacylphosphine oxide), a peroxy-bis(monoacylphosphane oxide), an azo-bis(alpha- hydroxy ketone), a peroxy-bis(alpha-hydroxy ketone), an azo-bis(1,2-diketone), a peroxy- bis(1,2-diketone), a germanium based compound, tert-butyl 7-methyl-7-(tert- butylazo)peroxyoctanoate, or combinations thereof.

41. The process of claim 40 wherein the polymerization initiator is a bisacylphosphine oxide or a bis(acyl)phosphane oxide.

42. The process of any one of claims 32 to 40 that is in the form of a hydrogel and wherein the reactive composition contains one or more silicone-containing components, and the grafting composition contains one or more hydrophilic reactive components.

43. The process of any one of claims 32 to 42 wherein the reactive composition, the grafting composition, or both the reactive composition and the grafting composition contain one or more additives selected from UV absorbers, photochromic compounds, pharmaceutical compounds, nutraceutical compounds, antimicrobial compounds, reactive tints, pigments, copolymerizable dyes, non-polymerizable dyes, release agents, wetting agents, and release agents.

44. The process of any one of claims 32 to 43 wherein the process further comprises: following step (e), contacting the crosslinked substrate network with a second grafting composition containing one or more ethylenically unsaturated compounds and activating retained covalently bound activatable free radical initiator such that the second grafting compositionAttorney Docket No.: VTN6149WOPCT1 polymerizes with the crosslinked substrate network outside of the selective regions and optionally partially within the selective regions.

45. The process of any one of claims 32 to 44 wherein the process steps (a) and (b) are performed in a mold assembly comprised of a front mold and a back mold, the front mold and a back mold defining and enclosing a cavity in the shape of the ophthalmic device therebetween, and process steps (c), (d), and (e) are performed in the mold assembly after the back mold has been removed.

46. The ophthalmic device of claim 1 or claim 17 wherein the selective regions form a pattern.

47. The ophthalmic device of claim 1 or claim 17 wherein the selective regions form a fiduciary marker.

48. The ophthalmic device of claim 1 or claim 17 wherein the selective regions form a barcode.